LAG3 and melanoma: Especially noteworthy is the combination of relatlimab (anti-LAG-3) and nivolumab (anti-PD-1), which has shown promising preliminary efficacy in melanoma patients previously unresponsive to anti-PD-1/PD-L1 therapy (NCT01968109) (86, 87).